Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Open access
Valpione, Sara, Pasquali, Sandro, Campana, Luca Giovanni, Piccin, Luisa, Mocellin, Simone, Pigozzo, Jacopo, Chiarion-Sileni, Vanna · 2018 · Journal of Translational Medicine

Abstract

BACKGROUND: Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity. METHODS: We performed a prospective study aimed at analyzing potential clinical and biological markers associated with immune-related toxicity in patients treated with ipilimumab (3 mg/kg, q3w). We enrolled 140 consecutive melanoma patients treated with ipilimumab for metastatic disease. The following prospectively collected data were utilized: patient characteristics, previous therapies, level of circulating biomarkers associated with tumour burden or immune-inflammation status (lactic dehydrogenase, C-reactive protein, β2-microglobulin, vascular endothelial growth factor, interleukin-2, interleukin-6, S-100, alkaline phosphatase, transaminases) and blood cells subsets (leukocyte and lymphocyte subpopulations). Logistic regression was used for multivariate analysis of data. RESULTS: Out of 140 patients, 36 (26%) experienced a severe adverse event, 33 (24%) discontinued treatment for severe toxicity. Among the immune-profile biomarkers analyzed, only interleukin-6 was associated with the risk of toxicity. Female patients had a further increase of immune-related adverse events. Low baseline interleukin-6 serum levels (OR = 2.84, 95% CI 1.34-6.03, P = 0.007) and sex female (OR = 1.5, 95% CI 1.06-2.16 P = 0.022) and were significant and independent risk factors for immune related adverse events. CONCLUSIONS: Baseline IL6 serum levels and female sex were significantly and independently associated with higher risk of severe toxicity and could be exploited in clinical practice to personalize toxicity surveillance in patients treated with ipilimumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-018-1467-x

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Hierarchical cluster analysis of covariates. The aggregation of covariates is represented in the cluster analysis using Hoeffding’s D as the (dis)similarity measure. This graphically presents the information concerning which observations are grouped together at various levels of similarity and dissimilarity. Vertical lines extend up for each observation, and at various (dis)similarity values, these lines are connected to the lines from other observations with a horizontal line. The height of the vertical lines and the range of the (dis)similarity axis give visual clues about the strength of the clustering. The variable severe toxicity is shown in the right upper corner, in proximity with gender and IL6. Toxicity does not cluster with any other investigated markers
Fig. 1 Hierarchical cluster analysis of covariates. The aggregation of covariates is represented in the cluster analysis using Hoeffding’s D as the (dis)similarity measure. This graphically presents the information concerning which observations are grouped together at various levels of similarity and dissimilarity. Vertical lines extend up for each observation, and at various (dis)similarity values, these lines are connected to the lines from other observations with a horizontal line. The height of the vertical lines and the range of the (dis)similarity axis give visual clues about the strength of the clustering. The variable severe toxicity is shown in the right upper corner, in proximity with gender and IL6. Toxicity does not cluster with any other investigated markersCC BY · PubMed Central
Fig. 2 Visual representation of the correlation between baseline IL6 levels, sex and risk of toxicity. The figure depicts the correlation between baseline interleukin-6 (IL6) levels, sex and risk of toxicity (logarithmic scale for the risk). The risk of toxicity decreases with higher IL6 concentrations for both genders. Female patients have, for the same blood concentrations of IL6, a higher risk for toxicity than men
Fig. 2 Visual representation of the correlation between baseline IL6 levels, sex and risk of toxicity. The figure depicts the correlation between baseline interleukin-6 (IL6) levels, sex and risk of toxicity (logarithmic scale for the risk). The risk of toxicity decreases with higher IL6 concentrations for both genders. Female patients have, for the same blood concentrations of IL6, a higher risk for toxicity than menCC BY · PubMed Central
Fig. 3 Survival of patients according to IL6 levels. Kaplan–Meier curves showing overall survival (OS) of patients relative to baseline circulating IL6 concentration. The continuous line presents patients with normal baseline IL6, the dotted line the patients with elevated baseline IL6. UNL upper normal limit
Fig. 3 Survival of patients according to IL6 levels. Kaplan–Meier curves showing overall survival (OS) of patients relative to baseline circulating IL6 concentration. The continuous line presents patients with normal baseline IL6, the dotted line the patients with elevated baseline IL6. UNL upper normal limitCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 209

Metadata

Authors
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V.
Affiliations
  • University of Padua (IT)
  • Istituto Oncologico Veneto (IT)
Corresponding author
Valpione, Sara
Venue
Journal of Translational Medicine
Published
2018-04-11
Volume
16
Issue
1
Pages
94-94
ISSN
1479-5876 (ISSN-L)
OpenAlex
W2797107996
Cited by
201
References
48
Citations by year
2026: 17 · 2025: 27 · 2024: 20 · 2023: 34 · 2022: 35 · 2021: 29 · 2020: 27 · 2019: 7 · 2018: 4
FWCI
6.30
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research Explorer (The University of Manchester) (submittedVersion, cc-by)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by)
Funders
European Society for Medical Oncology (Clinical Research Fellowship grant 2015-2016)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
ipilimumab, CTLA-4 blockade, immune-related adverse events, interleukin-6, sex differences, melanoma, prognostic factors, immunotoxicity, immune checkpoint inhibitors
MeSH terms
Adult, Aged, Aged, 80 and over, Female, Humans, Immunotherapy, Male, Middle Aged, Prognosis, Risk Factors, Sex Characteristics, Biomarkers, Tumor, Autoimmunity, Interleukin-6, Cluster Analysis, Kaplan-Meier Estimate, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. https://app.cochat.ai/papers/10.1186/s12967-018-1467-x
The paper
Valpione, S., Pasquali, S., Campana, L. G., Piccin, L., Mocellin, S., Pigozzo, J., & Chiarion-Sileni, V. (2018). Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. Journal of Translational Medicine. https://doi.org/10.1186/s12967-018-1467-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.